Internal Med Medical News about treatment of rheumatoid arthritis

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions
Future Rheumatology, 10/02/07

Nordstrom, D.C., et al. - Fewer than 40% of newly diagnosed patients with rheumatoid arthritis (RA) reach remission with a combination of traditional DMARDs, and therefore new effective therapies are still needed. Proinflammatory cytokines, such as TNF-alpha and IL-1, are important pathogenetic mediators in RA and related conditions. Targeted therapies against these cytokines and downstream inflammatory mediators have greatly added to the therapeutic arsenal and brought new hope to patients in providing physicians with new effective treatment options

<< Previous
Screening for Colorectal Neoplasms With New Fecal Occult Blood...

Next >>
Systemic lupus erythematosus: an international perspective on...

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09 Relevance Score: 90%

Update on the Management of Pain in Arthritis and the Use of Cyclooxygenase-2 Inhibitors
Current Pain and Headache Reports, 11/06/09 Relevance Score: 90%

The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
Rheumatology International, 10/28/09 Relevance Score: 90%

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09 Relevance Score: 90%

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09 Relevance Score: 90%